Ocular Therapeutix to Reveal Detailed SOL-1 Phase 3 Data at Macula Society Meeting—Investor Webcast Follows Key Disclosure

Crucial SOL-1 Clinical Trial Data to Be Unveiled on February 27, 2026

All eyes are on Ocular Therapeutix as the company prepares to present detailed results from its Phase 3 SOL-1 trial of AXPAXLI™ (OTX-TKI) for wet age-related macular degeneration (wet AMD) at the 49th Macula Society Annual Meeting in San Diego. The pivotal symposium is set for Friday, February 27, 2026, with new data revealed starting at 1:00 PM PT (4:00 PM ET).

Simultaneous SEC Filing and Web Access to Symposium Data Marks Transparency

Investors and the ophthalmic community will have access to the full SOL-1 presentation deck, as slides will be made available via a Current Report on Form 8-K filed with the SEC at 4:00 PM ET on the day of the symposium. Ocular Therapeutix will also post these materials on its website, reinforcing the transparency of this major clinical milestone.

Investor Webcast and Live Q&A: Engaging the Financial and Scientific Community

Ocular is hosting a dedicated investor webcast and conference call on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations in detail. The webcast will feature prepared remarks and a live question-and-answer session with company leadership and leading experts in retinal medicine, offering an in-depth look at the newly disclosed data and what it portends for the company's pipeline and the wet AMD treatment landscape.

Key Product Pipeline: AXPAXLI, DEXTENZA, and OTX-TIC Support Strategic Growth

AXPAXLI, Ocular's investigational axitinib-based hydrogel, stands at the forefront of the company's late-stage pipeline. Currently in Phase 3 trials for both wet AMD and diabetic retinal disease, its visibility is being amplified through these new data disclosures. The company is also advancing its proprietary ELUTYX™ hydrogel technology across commercial and investigational assets—including FDA-approved DEXTENZA® and the OTX-TIC glaucoma candidate, the latter having completed Phase 2 studies for open-angle glaucoma and ocular hypertension.

Investor Takeaway: Key Data Milestone for Wet AMD—Events Worth Watching

The sequential unveiling of detailed Phase 3 clinical data and real-time investor engagement underscores a major catalyst for Ocular Therapeutix. With SOL-1 results poised to inform regulatory and commercialization pathways for AXPAXLI, both industry stakeholders and shareholders will want to scrutinize these presentations closely. The company’s clear focus on transparency, multi-platform innovation, and pipeline advancement set the stage for potentially pivotal developments in the months ahead.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI